Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Tacrolimus
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Dailiport 1mg modified-release capsules
0802020T0BKABAN
|
Dailiport | Tacrolimus | Malignant Disease and Immunosuppression | 43 |
|
Tacrolimus 1mg modified-release capsules
0802020T0AAANAN
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 32 |
|
Tacrolimus 2.5mg/5ml oral liquid
0802020T0AAAGAG
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 32 |
|
Tacrolimus 1mg gran for susp sachets sugar free
0802020T0AAAWAW
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 23 |
|
Tacrolimus 5mg capsules
0802020T0AAAAAA
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 23 |
|
Tacrolimus 750microgram capsules
0802020T0AABFBF
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 18 |
|
Tacrolimus 5mg modified-release capsules
0802020T0AAAPAP
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 17 |
|
Dailiport 0.5mg modified-release capsules
0802020T0BKAAAM
|
Dailiport | Tacrolimus | Malignant Disease and Immunosuppression | 12 |
|
Tacrolimus 200microgram gran for susp sachets sugar free
0802020T0AAAVAV
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 12 |
|
Tacrolimus 3mg modified-release capsules
0802020T0AAATAT
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 9 |
|
Tacrolimus 500microgram modified-release capsules
0802020T0AAAMAM
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 9 |
|
Dailiport 3mg modified-release capsules
0802020T0BKACAT
|
Dailiport | Tacrolimus | Malignant Disease and Immunosuppression | 5 |
|
Dailiport 2mg modified-release capsules
0802020T0BKAEBJ
|
Dailiport | Tacrolimus | Malignant Disease and Immunosuppression | 4 |
|
Tacrolimus 1mg modified-release tablets
0802020T0AABCBC
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 4 |
|
Tacrolimus 2mg modified-release capsules
0802020T0AABJBJ
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 2 |
|
Dailiport 5mg modified-release capsules
0802020T0BKADAP
|
Dailiport | Tacrolimus | Malignant Disease and Immunosuppression | 1 |
|
Tacrolimus 4mg modified-release tablets
0802020T0AABEBE
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | 1 |
|
Capexion 0.5mg capsules
0802020T0BHAAAF
|
Capexion | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Capexion 1mg capsules
0802020T0BHABAB
|
Capexion | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Capexion 5mg capsules
0802020T0BHACAA
|
Capexion | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Perixis 0.5mg capsules
0802020T0BIAAAF
|
Perixis | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Perixis 1mg capsules
0802020T0BIABAB
|
Perixis | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Perixis 5mg capsules
0802020T0BIACAA
|
Perixis | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Prograf 5mg/1ml solution for infusion ampoules
0802020T0BBACAC
|
Prograf | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tacni 0.5mg capsules
0802020T0BGAAAF
|
Tacni | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.